Clinical Trial Update: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating intrahepatic delivery of SD-101 with checkpoint blockade for metastatic uveal melanoma in the liver has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• SD-101

Snippet

Sponsor: TriSalus Life Sciences, Inc. | Conditions: Metastatic Uveal Melanoma in the Liver | Phase 1 | Status: TERMINATED